Critical Care Management of Decompensated Right Heart Failure in Pulmonary Arterial Hypertension Patients – An Ongoing Approach

1Galiè N, Humbert M, Vachiery JL, et al; ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67-119.Galiè N Humbert M Vachiery JL et al; ESC Scientific Document Group 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT) Eur Heart J 201637 1 67 11910.1093/eurheartj/ehv31726320113Search in Google Scholar

2Galiè N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801889.Galiè N Channick RN Frantz RP et al Risk stratification and medical therapy of pulmonary arterial hypertension Eur Respir J 201953 1 180188910.1183/13993003.01889-2018635134330545971Search in Google Scholar

3Konstam MA, Kiernan MS, Bernstein D, et al C; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; and Council on Cardiovascular Surgery and Anesthesia. Evaluation and management of right-sided heart failure: a scientific statement from the American Heart Association. Circulation. 2018;137(20):e578-e622.Konstam MA Kiernan MS Bernstein D et al C; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; and Council on Cardiovascular Surgery and Anesthesia. Evaluation and management of right-sided heart failure: a scientific statement from the American Heart Association Circulation 2018137 20 e578 e622Search in Google Scholar

4Haddad F, Doyle R, Murphy DJ, Hunt SA. Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure. Circulation. 2008;117(13):1717-31.Haddad F Doyle R Murphy DJ Hunt SA Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure Circulation 2008117 13 1717 3110.1161/CIRCULATIONAHA.107.65358418378625Search in Google Scholar

5Nowroozpoor A, Malekmohammad M, Seyyedi SR, Hashemian SM. Pulmonary hypertension in intensive care units: an updated review. Tanaffos. 2019;18(3):180-207.Nowroozpoor A Malekmohammad M Seyyedi SR Hashemian SM Pulmonary hypertension in intensive care units: an updated review Tanaffos 201918 3 180 207Search in Google Scholar

6Bauchmuller K, Condliffe R, Southern J, et al. Critical care outcomes in patients with pre-existing pulmonary hypertension: insights from the ASPIRE registry. ERJ Open Res. 2021;7(2):00046-2021.Bauchmuller K Condliffe R Southern J et al Critical care outcomes in patients with pre-existing pulmonary hypertension: insights from the ASPIRE registry ERJ Open Res 20217 2 00046 202110.1183/23120541.00046-2021802180233834051Search in Google Scholar

7Huynh TN, Weigt SS, Sugar CA, Shapiro S, Kleerup EC. Prognostic factors and outcomes of patients with pulmonary hypertension admitted to the intensive care unit. J Crit Care. 2012;27(6):739.e7-13.Huynh TN Weigt SS Sugar CA Shapiro S Kleerup EC Prognostic factors and outcomes of patients with pulmonary hypertension admitted to the intensive care unit J Crit Care 201227 6 739e7-1310.1016/j.jcrc.2012.08.00623089677Search in Google Scholar

8Saydain G, Awan A, Manickam P, Kleinow P, Badr S. Pulmonary hypertension an independent risk factor for death in intensive care unit: correlation of hemodynamic factors with mortality. Clin Med Insights Circ Respir Pulm Med. 2015;9:27-33.Saydain G Awan A Manickam P Kleinow P Badr S Pulmonary hypertension an independent risk factor for death in intensive care unit: correlation of hemodynamic factors with mortality Clin Med Insights Circ Respir Pulm Med 2015927 3310.4137/CCRPM.S22199447916726124692Search in Google Scholar

9Sztrymf B, Souza R, Bertoletti L, et al. Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. Eur Respir J. 2010;35(6):1286-93.Sztrymf B Souza R Bertoletti L et al Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension Eur Respir J 201035 6 1286 9310.1183/09031936.0007020919897557Search in Google Scholar

10Jentzer JC, Mathier MA. Pulmonary hypertension in the intensive care unit. J Intensive Care Med. 2016;31(6):369-85.Jentzer JC Mathier MA Pulmonary hypertension in the intensive care unit J Intensive Care Med 201631 6 369 8510.1177/088506661558365225944777Search in Google Scholar

11Kurzyna M, Zyłkowska J, Fijałkowska A, et al. Characteristics and prognosis of patients with decompensated right ventricular failure during the course of pulmonary hypertension. Kardiol Pol. 2008;66(10):1033-9.Kurzyna M Zyłkowska J Fijałkowska A et al Characteristics and prognosis of patients with decompensated right ventricular failure during the course of pulmonary hypertension Kardiol Pol 200866 10 1033 9Search in Google Scholar

12Campo A, Mathai SC, Le Pavec J, et al. Outcomes of hospitalisation for right heart failure in pulmonary arterial hypertension. Eur Respir J. 2011;38(2):359-67.Campo A Mathai SC Le Pavec J et al Outcomes of hospitalisation for right heart failure in pulmonary arterial hypertension Eur Respir J 201138 2 359 6710.1183/09031936.0014831021310884Search in Google Scholar

13Haddad F, Fuh E, Peterson T, et al. Incidence, correlates, and consequences of acute kidney injury in patients with pulmonary arterial hypertension hospitalized with acute right-side heart failure. J Cardiac Fail. 2011;17(7):533-9.Haddad F Fuh E Peterson T et al Incidence, correlates, and consequences of acute kidney injury in patients with pulmonary arterial hypertension hospitalized with acute right-side heart failure J Cardiac Fail 201117 7 533 910.1016/j.cardfail.2011.03.00321703524Search in Google Scholar

14Torbic H. Management of pulmonary arterial hypertension in the ICU. J Pharm Pract. 2019;32(3):303-13.Torbic H Management of pulmonary arterial hypertension in the ICU J Pharm Pract 201932 3 303 1310.1177/089719001983811030909801Search in Google Scholar

15Olsson KM, Halank M, Egenlauf B, et al. Decompensated right heart failure, intensive care and perioperative management in patients with pulmonary hypertension: Updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol. 2018;272S:46-52.Olsson KM Halank M Egenlauf B et al Decompensated right heart failure, intensive care and perioperative management in patients with pulmonary hypertension: Updated recommendations from the Cologne Consensus Conference 2018 Int J Cardiol 2018272S46 5210.1016/j.ijcard.2018.08.08130190155Search in Google Scholar

16Hoeper MM, Benza RL, Corris P, et al. Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension. Eur Respir J. 2019;53(1):1801906.Hoeper MM Benza RL Corris P et al Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension Eur Respir J 201953 1 180190610.1183/13993003.01906-2018635138530545979Search in Google Scholar

17Morrell NW, Aldred MA, Chung WK, et al. Genetics and genomics of pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801899.Morrell NW Aldred MA Chung WK et al Genetics and genomics of pulmonary arterial hypertension Eur Respir J 201953 1 180189910.1183/13993003.01899-2018635133730545973Search in Google Scholar

18Hemnes AR, Beck GJ, Newman JH, et al; PVDOMICS Study Group. PVDOMICS: A multi-center study to improve understanding of pulmonary vascular disease through phenomics. Circ Res. 2017;121(10):1136-9.Hemnes AR Beck GJ Newman JH et al PVDOMICS Study Group. PVDOMICS: A multi-center study to improve understanding of pulmonary vascular disease through phenomics Circ Res 2017121 10 1136 910.1161/CIRCRESAHA.117.311737568556129074534Search in Google Scholar

19Georgescu AM, Moldovan C, Szederjesi J, Georgescu D, Azamfirei L. Echocardiographic characteristics of pulmonary arterial hypertension in children with horizontally transmitted HIV. Adv Clin Exp Med. 2017;26(3):475-81.Georgescu AM Moldovan C Szederjesi J Georgescu D Azamfirei L Echocardiographic characteristics of pulmonary arterial hypertension in children with horizontally transmitted HIV Adv Clin Exp Med 201726 3 475 8110.17219/acem/6224428791823Search in Google Scholar

20Weatherald J, Reis A, Sitbon O, Humbert M. Pulmonary arterial hypertension registries: past, present and into the future. Eur Respir Rev. 2019;28(154):190128.Weatherald J Reis A Sitbon O Humbert M Pulmonary arterial hypertension registries: past, present and into the future Eur Respir Rev 201928 154 19012810.1183/16000617.0128-201931852747Search in Google Scholar

21Swinnen K, Quarck R, Godinas L, Belge C, Delcroix M. Learning from registries in pulmonary arterial hypertension: pitfalls and recommendations. Eur Respir Rev. 2019;28(154):190050.Swinnen K Quarck R Godinas L Belge C Delcroix M Learning from registries in pulmonary arterial hypertension: pitfalls and recommendations Eur Respir Rev 201928 154 19005010.1183/16000617.0050-201931852746Search in Google Scholar

22Maron BA, Galiè N. Diagnosis, treatment, and clinical management of pulmonary arterial hypertension in the contemporary era: A Review. JAMA Cardiol. 2016;1(9):1056-65.Maron BA Galiè N Diagnosis, treatment, and clinical management of pulmonary arterial hypertension in the contemporary era: A Review JAMA Cardiol 20161 9 1056 6510.1001/jamacardio.2016.4471517749127851839Search in Google Scholar

23McLaughlin VV, Archer SL, Badesch DB, et al; American College of Cardiology Foundation Task Force on Expert Consensus Documents; American Heart Association; American College of Chest Physicians; American Thoracic Society, Inc; Pulmonary Hypertension Association. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53(17):1573-619.McLaughlin VV Archer SL Badesch DB et al American College of Cardiology Foundation Task Force on Expert Consensus Documents; American Heart Association; American College of Chest Physicians; American Thoracic Society, Inc; Pulmonary Hypertension Association. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association J Am Coll Cardiol 200953 17 1573 61910.1016/j.jacc.2009.01.00419389575Search in Google Scholar

24Farber HW, Miller DP, Poms AD, et al. Five-year outcomes of patients enrolled in the REVEAL Registry. Chest. 2015;148(4):1043-54.Farber HW Miller DP Poms AD et al Five-year outcomes of patients enrolled in the REVEAL Registry Chest 2015148 4 1043 5410.1378/chest.15-030026066077Search in Google Scholar

25Sitbon O, Sattler C, Bertoletti L, et al. Initial dual oral combination therapy in pulmonary arterial hypertension. Eur Respir J. 2016;47(6):1727-36.Sitbon O Sattler C Bertoletti L et al Initial dual oral combination therapy in pulmonary arterial hypertension Eur Respir J 201647 6 1727 3610.1183/13993003.02043-201526989105Search in Google Scholar

26Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010;137(2):376-87.Badesch DB Raskob GE Elliott CG et al Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry Chest 2010137 2 376 8710.1378/chest.09-114019837821Search in Google Scholar

27Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173(9):1023-30.Humbert M Sitbon O Chaouat A et al Pulmonary arterial hypertension in France: results from a national registry Am J Respir Crit Care Med 2006173 9 1023 3010.1164/rccm.200510-1668OC16456139Search in Google Scholar

28Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur Respir J. 2007;30(1):104-9.Peacock AJ Murphy NF McMurray JJ Caballero L Stewart S An epidemiological study of pulmonary arterial hypertension Eur Respir J 200730 1 104 910.1183/09031936.0009230617360728Search in Google Scholar

29McGoon MD, Benza RL, Escribano-Subias P. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol. 2013;62(25 Suppl):D51-9.McGoon MD Benza RL Escribano-Subias P Pulmonary arterial hypertension: epidemiology and registries J Am Coll Cardiol 201362 25 Suppl D51 910.21693/1933-088X-13.1.21Search in Google Scholar

30Bergot E, De Leotoing L, Bendjenana H, et al. Hospital burden of pulmonary arterial hypertension in France. PLoS One. 2019;14(9):e0221211.Bergot E De Leotoing L Bendjenana H et al Hospital burden of pulmonary arterial hypertension in France PLoS One 201914 9 e022121110.1371/journal.pone.0221211675279731536491Search in Google Scholar

31D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343-9.D’Alonzo GE Barst RJ Ayres SM et al Survival in patients with primary pulmonary hypertension Results from a national prospective registry. Ann Intern Med 1991115 5 343 910.7326/0003-4819-115-5-3431863023Search in Google Scholar

32Humbert M, Sitbon O, Yaïci A, et al; French pulmonary arterial hypertension network. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J. 2010;36(3):549-55.Humbert M Sitbon O Yaïci A et al French pulmonary arterial hypertension network. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension Eur Respir J 201036 3 549 5510.1183/09031936.0005701020562126Search in Google Scholar

33Thenappan T, Shah SJ, Rich S, Tian L, Archer SL, Gomberg-Maitland M. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J. 2010;35(5):1079-87.Thenappan T Shah SJ Rich S Tian L Archer SL Gomberg-Maitland M Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation Eur Respir J 201035 5 1079 8710.1183/09031936.00072709878256420032020Search in Google Scholar

34Silber D, Lachmann J. Invasive hemodynamics of pulmonary disease and the right ventricle. Interv Cardiol Clin. 2017;6(3):329-43.Silber D Lachmann J Invasive hemodynamics of pulmonary disease and the right ventricle Interv Cardiol Clin 20176 3 329 4310.1016/j.iccl.2017.03.00428600088Search in Google Scholar

35Moscucci M (ed). Grossman & Baim’s Cardiac Catheterization, Angiography, and Intervention, Wolters Kluwer, 9 th Ed., 2021.Moscucci M (ed) Grossman & Baim’s Cardiac Catheterization, Angiography, and Intervention, Wolters Kluwer, 9 th Ed 2021Search in Google Scholar

36Benza RL, Gomberg-Maitland M, Elliott CG, et al. Predicting survival in patients with pulmonary arterial hypertension: The REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies. Chest. 2019;156(2):323-37.Benza RL Gomberg-Maitland M Elliott CG et al Predicting survival in patients with pulmonary arterial hypertension: The REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies Chest 2019156 2 323 3710.1016/j.chest.2019.02.00430772387Search in Google Scholar

37Benza RL, Kanwar MK, Raina A, et al. Development and validation of an abridged version of the REVEAL 2.0 risk score calculator, REVEAL Lite 2, for use in patients with pulmonary arterial hypertension. Chest. 2021;159(1):337-46.Benza RL Kanwar MK Raina A et al Development and validation of an abridged version of the REVEAL 2.0 risk score calculator, REVEAL Lite 2, for use in patients with pulmonary arterial hypertension Chest 2021159 1 337 4610.1016/j.chest.2020.08.2069746263932882243Search in Google Scholar

38Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017;50(2):1700889.Boucly A Weatherald J Savale L et al Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension Eur Respir J 201750 2 170088910.1183/13993003.00889-201728775050Search in Google Scholar

39Ranchoux B, Harvey LD, Ayon RJ, et al. Endothelial dysfunction in pulmonary arterial hypertension: an evolving landscape (2017 Grover Conference Series). Pulm Circ. 2018;8(1):2045893217752912.Ranchoux B Harvey LD Ayon RJ et al Endothelial dysfunction in pulmonary arterial hypertension: an evolving landscape (2017 Grover Conference Series) Pulm Circ 20188 1 204589321775291210.1177/2045893217752912579869129283043Search in Google Scholar

40Yildiz M, Sahin A, Behnes M, Akin İ. An expanding role of biomarkers in pulmonary arterial hypertension. Curr Pharm Biotechnol. 2017;18(6):491-4.Yildiz M Sahin A Behnes M Akin İ An expanding role of biomarkers in pulmonary arterial hypertension Curr Pharm Biotechnol 201718 6 491 410.2174/138920101866617061508251028641568Search in Google Scholar

41Kanwar MK. Biomarkers in pulmonary arterial hypertension: Moving closer toward precision medicine? J Heart Lung Transplant. 2020;39(4):287-8.Kanwar MK Biomarkers in pulmonary arterial hypertension: Moving closer toward precision medicine? J Heart Lung Transplant 202039 4 287 810.1016/j.healun.2020.02.02032199588Search in Google Scholar

42Fijalkowska A, Kurzyna M, Torbicki A, et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest. 2006;129(5):1313-21.Fijalkowska A Kurzyna M Torbicki A et al Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension Chest 2006129 5 1313 2110.1378/chest.129.5.131316685024Search in Google Scholar

43Warwick G, Thomas PS, Yates DH. Biomarkers in pulmonary hypertension. Eur Respir J. 2008;32(2):503-12.Warwick G Thomas PS Yates DH Biomarkers in pulmonary hypertension Eur Respir J 200832 2 503 1210.1183/09031936.0016030718669790Search in Google Scholar

44Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975.Ponikowski P Voors AA Anker SD et al 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC Eur J Heart Fail 201618 8 891 97510.1002/ejhf.59227207191Search in Google Scholar

45Rubio-Gracia J, Giménez-López I, Josa-Laorden C, et al. Prognostic value of multimodal assessment of congestion in acute heart failure. Rev Clin Esp (Barc). 2021;221(4):198-206.Rubio-Gracia J Giménez-López I Josa-Laorden C et al Prognostic value of multimodal assessment of congestion in acute heart failure Rev Clin Esp (Barc) 2021221 4 198 20610.1016/j.rceng.2019.10.01333998498Search in Google Scholar

46Pezzuto B, Badagliacca R, Poscia R, et al. Circulating biomarkers in pulmonary arterial hypertension: update and future direction. J Heart Lung Transplant. 2015;34:282-305.Pezzuto B Badagliacca R Poscia R et al Circulating biomarkers in pulmonary arterial hypertension: update and future direction J Heart Lung Transplant 201534282 30510.1016/j.healun.2014.12.00525682555Search in Google Scholar

47Hemnes AR. Current and emerging biomarkers for pulmonary hypertension. Adv Pulm Hypertens. 2018;16:136-40.Hemnes AR Current and emerging biomarkers for pulmonary hypertension Adv Pulm Hypertens 201816136 4010.21693/1933-088X-16.3.136Search in Google Scholar

48Simpson CE, Damico RL, Hassoun PM, et al. Noninvasive prognostic biomarkers for left-sided heart failure as predictors of survival in pulmonary arterial hypertension. Chest. 2020;157(6):1606-16.Simpson CE Damico RL Hassoun PM et al Noninvasive prognostic biomarkers for left-sided heart failure as predictors of survival in pulmonary arterial hypertension Chest 2020157 6 1606 1610.1016/j.chest.2019.12.037726844631987881Search in Google Scholar

49Samokhin AO, Stephens T, Wertheim BM, et al. NEDD9 targets COL3A1 to promote endothelial fibrosis and pulmonary arterial hypertension. Sci Transl Med. 2018;10(445):eaap7294.Samokhin AO Stephens T Wertheim BM et al NEDD9 targets COL3A1 to promote endothelial fibrosis and pulmonary arterial hypertension Sci Transl Med 201810 445 eaap729410.1126/scitranslmed.aap7294622302529899023Search in Google Scholar

50Coons JC, Pogue K, Kolodziej AR, Hirsch GA, George MP. Pulmonary arterial hypertension: a pharmacotherapeutic update. Curr Cardiol Rep. 2019;21(11):141.Coons JC Pogue K Kolodziej AR Hirsch GA George MP Pulmonary arterial hypertension: a pharmacotherapeutic update Curr Cardiol Rep 201921 11 14110.1007/s11886-019-1235-431758342Search in Google Scholar

51Dodson MW, Brown LM, Elliott CG. Pulmonary arterial hypertension. Heart Fail Clin. 2018;14(3):255-69.Dodson MW Brown LM Elliott CG Pulmonary arterial hypertension Heart Fail Clin 201814 3 255 6910.1016/j.hfc.2018.02.00329966625Search in Google Scholar

52Price LC, Dimopoulos K, Marino P, et al. The CRASH report: emergency management dilemmas facing acute physicians in patients with pulmonary arterial hypertension. Thorax. 2017;72(11):1035-45.Price LC Dimopoulos K Marino P et al The CRASH report: emergency management dilemmas facing acute physicians in patients with pulmonary arterial hypertension Thorax 201772 11 1035 4510.1136/thoraxjnl-2016-20972528904006Search in Google Scholar

53Cassady SJ, Ramani GV. Right heart failure in pulmonary hypertension. Cardiol Clin. 2020;38(2):243-55.Cassady SJ Ramani GV Right heart failure in pulmonary hypertension Cardiol Clin 202038 2 243 5510.1016/j.ccl.2020.02.00132284101Search in Google Scholar

54Siehr SL, Ivy DD, Miller-Reed K, Ogawa M, Rosenthal DN, Feinstein JA. Children with pulmonary arterial hypertension and prostanoid therapy: long-term hemodynamics. J Heart Lung Transplant. 2013;32(5):546-52.Siehr SL Ivy DD Miller-Reed K Ogawa M Rosenthal DN Feinstein JA Children with pulmonary arterial hypertension and prostanoid therapy: long-term hemodynamics J Heart Lung Transplant 201332 5 546 5210.1016/j.healun.2013.01.1055376015923453572Search in Google Scholar

55Sandoval J. Interventional therapies in pulmonary hypertension. Rev Esp Cardiol (Engl Ed). 2018;71(7):565-74.Sandoval J Interventional therapies in pulmonary hypertension Rev Esp Cardiol (Engl Ed) 201871 7 565 7410.1016/j.rec.2018.02.00229545075Search in Google Scholar

56Vonk Noordegraaf A, Haddad F, Chin KM, et al. Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. J Am Coll Cardiol. 2013;62:D22-33.Vonk Noordegraaf A Haddad F Chin KM et al Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology J Am Coll Cardiol 201362D22 3310.1016/j.jacc.2013.10.02724355638Search in Google Scholar

57Vonk Noordegraaf A, Chin KM, Haddad F, et al. Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update. Eur Respir J. 2019;53(1):1801900.Vonk Noordegraaf A Chin KM Haddad F et al Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update Eur Respir J 201953 1 180190010.1183/13993003.01900-2018635134430545976Search in Google Scholar

58Mehra MR, Park MH, Landzberg MJ, Lala A, Waxman AB; International Right Heart Failure Foundation Scientific Working Group. Right heart failure: toward a common language. J Heart Lung Transplant. 2014;33(2):123-6.Mehra MR Park MH Landzberg MJ Lala A Waxman AB International Right Heart Failure Foundation Scientific Working Group. Right heart failure: toward a common language J Heart Lung Transplant 201433 2 123 610.1016/j.healun.2013.10.01524268184Search in Google Scholar

59Harjola VP, Mebazaa A, Čelutkienė J, et al. Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. Eur J Heart Fail. 2016;18(3):226-41.Harjola VP Mebazaa A Čelutkienė J et al Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology Eur J Heart Fail 201618 3 226 4110.1002/ejhf.47826995592Search in Google Scholar

60Inampudi C, Tedford RJ, Hemnes AR, et al. Treatment of right ventricular dysfunction and heart failure in pulmonary arterial hypertension. Cardiovasc Diagn Ther. 2020;10(5):1659-74.Inampudi C Tedford RJ Hemnes AR et al Treatment of right ventricular dysfunction and heart failure in pulmonary arterial hypertension Cardiovasc Diagn Ther 202010 5 1659 7410.21037/cdt-20-348766695633224779Search in Google Scholar

61Sanders JL, Koestenberger M, Rosenkranz S, Maron BA. Right ventricular dysfunction and long-term risk of death. Cardiovasc Diagn Ther. 2020;10(5):1646-58.Sanders JL Koestenberger M Rosenkranz S Maron BA Right ventricular dysfunction and long-term risk of death Cardiovasc Diagn Ther 202010 5 1646 5810.21037/cdt-20-450766695733224778Search in Google Scholar

62Hermens JA, Donker DW. Right ventricular failure in the ICU: a practical approach. Neth J Crit Care. 2018;26(3):111-7.Hermens JA Donker DW Right ventricular failure in the ICU: a practical approach Neth J Crit Care 201826 3 111 7Search in Google Scholar

63Rajagopalan N, Dohi K, Simon MA, et al. Right ventricular dyssynchrony in heart failure: a tissue Doppler imaging study. J Card Fail. 2006;12(4):263-7.Rajagopalan N Dohi K Simon MA et al Right ventricular dyssynchrony in heart failure: a tissue Doppler imaging study J Card Fail 200612 4 263 710.1016/j.cardfail.2006.02.00816679258Search in Google Scholar

64Vitarelli A, Mangieri E, Terzano C, et al. Three-dimensional echocardiography and 2D-3D speckle-tracking imaging in chronic pulmonary hypertension: diagnostic accuracy in detecting hemodynamic signs of right ventricular (RV) failure. J Am Heart Assoc. 2015;4(3):e001584.Vitarelli A Mangieri E Terzano C et al Three-dimensional echocardiography and 2D-3D speckle-tracking imaging in chronic pulmonary hypertension: diagnostic accuracy in detecting hemodynamic signs of right ventricular (RV) failure J Am Heart Assoc 20154 3 e00158410.1161/JAHA.114.001584439243825792128Search in Google Scholar

65Marik PE. Obituary: pulmonary artery catheter 1970 to 2013. Ann Intensive Care. 2013;3(1):38.Marik PE Obituary: pulmonary artery catheter 1970 to 2013 Ann Intensive Care 20133 1 3810.1186/2110-5820-3-38417548224286266Search in Google Scholar

66de Asua I, Rosenberg A. On the right side of the heart: Medical and mechanical support of the failing right ventricle. J Intensive Care Soc. 2017;18(2):113-20.de Asua I Rosenberg A On the right side of the heart: Medical and mechanical support of the failing right ventricle J Intensive Care Soc 201718 2 113 2010.1177/1751143716684357560642228979557Search in Google Scholar

67Litton E, Morgan M. The PiCCO monitor: a review. Anaesth Intensive Care. 2012;40(3):393-409.Litton E Morgan M The PiCCO monitor: a review Anaesth Intensive Care 201240 3 393 40910.1177/0310057X120400030422577904Search in Google Scholar

68Pearse RM, Ikram K, Barry J. Equipment review: an appraisal of the LiDCO plus method of measuring cardiac output. Crit Care. 2004;8(3):190-5.Pearse RM Ikram K Barry J Equipment review: an appraisal of the LiDCO plus method of measuring cardiac output Crit Care 20048 3 190 510.1186/cc285246889915153237Search in Google Scholar

69Sharma RK, Oliveira AC, Yang T, et al. Pulmonary arterial hypertension-associated changes in gut pathology and microbiota. ERJ Open Res. 2020;6(3):00253-2019.Sharma RK Oliveira AC Yang T et al Pulmonary arterial hypertension-associated changes in gut pathology and microbiota ERJ Open Res 20206 3 00253 201910.1183/23120541.00253-2019738305432743008Search in Google Scholar

70Ranchoux B, Bigorgne A, Hautefort A, et al. Gut-lung connection in pulmonary arterial hypertension. Am J Respir Cell Mol Biol. 2017;56(3):402-5.Ranchoux B Bigorgne A Hautefort A et al Gut-lung connection in pulmonary arterial hypertension Am J Respir Cell Mol Biol 201756 3 402 510.1165/rcmb.2015-0404LE28248132Search in Google Scholar

71Bandorski D, Bogossian H, Stempfl J, et al. Prognostic relevance of nonsustained ventricular tachycardia in patients with pulmonary hypertension. Biomed Res Int. 2016;2016:1327265.Bandorski D Bogossian H Stempfl J et al Prognostic relevance of nonsustained ventricular tachycardia in patients with pulmonary hypertension Biomed Res Int 20162016132726510.1155/2016/1327265520640828090536Search in Google Scholar

72Cannillo M, Grosso Marra W, et al. Supraventricular arrhythmias in patients with pulmonary arterial hypertension. Am J Cardiol. 2015;116(12):1883-9.Cannillo M Grosso Marra W et al Supraventricular arrhythmias in patients with pulmonary arterial hypertension Am J Cardiol 2015116 12 1883 910.1016/j.amjcard.2015.09.03926522342Search in Google Scholar

73Middleton JT, Maulik A, Lewis R, et al. Arrhythmic burden and outcomes in pulmonary arterial hypertension. Front Med (Lausanne). 2019;6:169.Middleton JT Maulik A Lewis R et al Arrhythmic burden and outcomes in pulmonary arterial hypertension Front Med (Lausanne) 2019616910.3389/fmed.2019.00169666400031396515Search in Google Scholar

74Mercurio V, Peloquin G, Bourji KI, et al. Pulmonary arterial hypertension and atrial arrhythmias: incidence, risk factors, and clinical impact. Pulm Circ. 2018;8(2):2045894018769874.Mercurio V Peloquin G Bourji KI et al Pulmonary arterial hypertension and atrial arrhythmias: incidence, risk factors, and clinical impact Pulm Circ 20188 2 204589401876987410.1177/2045894018769874591229129575972Search in Google Scholar

75Olsson KM, Nickel NP, Tongers J, Hoeper MM. Atrial flutter and fibrillation in patients with pulmonary hypertension. Int J Cardiol. 2013;167(5):2300-5.Olsson KM Nickel NP Tongers J Hoeper MM Atrial flutter and fibrillation in patients with pulmonary hypertension Int J Cardiol 2013167 5 2300 510.1016/j.ijcard.2012.06.02422727973Search in Google Scholar

76Granton J, Mercier O, De Perrot M. Management of severe pulmonary arterial hypertension. Semin Respir Crit Care Med. 2013;34(5):700-13.Granton J Mercier O De Perrot M Management of severe pulmonary arterial hypertension Semin Respir Crit Care Med 201334 5 700 1310.1055/s-0033-1356460Search in Google Scholar

77Cirulis MM, Ryan JJ, Archer SL. Pathophysiology, incidence, management, and consequences of cardiac arrhythmia in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Pulm Circ. 2019;9(1):2045894019834890.Cirulis MM Ryan JJ Archer SL Pathophysiology, incidence, management, and consequences of cardiac arrhythmia in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Pulm Circ 20199 1 204589401983489010.1177/2045894019834890Search in Google Scholar

78Bandorski D, Bogossian H, Ghofrani A, Schmitt J, Höltgen R. Tachykardien bei pulmonalarterieller hypertonie [Tachycardia and pulmonary arterial hypertension]. Herzschrittmacherther Elektrophysiol. 2020;31(1):33-8.Bandorski D Bogossian H Ghofrani A Schmitt J Höltgen R Tachykardien bei pulmonalarterieller hypertonie [Tachycardia and pulmonary arterial hypertension] Herzschrittmacherther Elektrophysiol 202031 1 33 810.1007/s00399-020-00668-wSearch in Google Scholar

79Grünig E, Benjamin N, Krüger U, et al. General measures and supportive therapy for pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol. 2018;272S:30-6.Grünig E Benjamin N Krüger U et al General measures and supportive therapy for pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018 Int J Cardiol 2018272S30 610.1016/j.ijcard.2018.08.085Search in Google Scholar

80Ponikowski P, Kirwan BA, Anker SD, et al; AFFIRM-AHF investigators. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet. 2020;396(10266):1895-904.Ponikowski P Kirwan BA Anker SD et al AFFIRM-AHF investigators. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial Lancet 2020396 10266 1895 90410.1016/S0140-6736(20)32339-4Search in Google Scholar

81DeFilippis EM, Van Spall HGC. In acute HF and iron deficiency, IV ferric carboxymaltose reduced HF hospitalizations, but not CV death, at 1 y. Ann Intern Med. 2021;174(4):JC45.DeFilippis EM Van Spall HGC In acute HF and iron deficiency, IV ferric carboxymaltose reduced HF hospitalizations, but not CV death, at 1 y Ann Intern Med 2021174 4 JC4510.7326/ACPJ202104200-04533819065Search in Google Scholar

82Thibault N, Morrill AM, Willett KC. Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review. Am J Ther. 2018;25(3):e333-e338.Thibault N Morrill AM Willett KC Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review Am J Ther 201825 3 e333 e33810.1097/MJT.000000000000046027175894Search in Google Scholar

83Carpenter E, Singh D, Dietrich E, Gums J. Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation. Ther Adv Drug Saf. 2019;10:2042098619888133.Carpenter E Singh D Dietrich E Gums J Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation Ther Adv Drug Saf 201910204209861988813310.1177/2042098619888133688002831807265Search in Google Scholar

84Moen CA, Burrell A, Dunning J. Does tranexamic acid stop haemoptysis? Interact Cardiovasc Thorac Surg. 2013;17(6):991-4.Moen CA Burrell A Dunning J Does tranexamic acid stop haemoptysis? Interact Cardiovasc Thorac Surg 201317 6 991 410.1093/icvts/ivt383382950023966576Search in Google Scholar

85Cantu J, Wang D, Safdar Z. Clinical implications of haemoptysis in patients with pulmonary arterial hypertension. Int J Clin Pract Suppl. 2012;(177):5-12.Cantu J Wang D Safdar Z Clinical implications of haemoptysis in patients with pulmonary arterial hypertension Int J Clin Pract Suppl 2012 177 5 1210.1111/ijcp.12004400178222943513Search in Google Scholar

86Franquiz MJ, Hines MC, Yeung SYA. Comparison of Two Weight-Based Desmopressin Dosing Strategies for Spontaneous Bleeding. Ann Pharmacother. 2018;52(6):527-32.Franquiz MJ Hines MC Yeung SYA Comparison of Two Weight-Based Desmopressin Dosing Strategies for Spontaneous Bleeding Ann Pharmacother 201852 6 527 3210.1177/106002801775235429332421Search in Google Scholar

87Konstantinides SV, Meyer G, Becattini C, et al; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543-603.Konstantinides SV Meyer G Becattini C et al ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS Eur Heart J 202041 4 543 60310.1093/eurheartj/ehz40531504429Search in Google Scholar

88Roberts DH, Lepore JJ, Maroo A, et al. Oxygen therapy improves cardiac index and pulmonary vascular resistance in patients with pulmonary hypertension. Chest 2001;120:1547-55.Roberts DH Lepore JJ Maroo A et al Oxygen therapy improves cardiac index and pulmonary vascular resistance in patients with pulmonary hypertension Chest 20011201547 5510.1378/chest.120.5.154711713133Search in Google Scholar

89Price LC, Wort SJ, Finney SJ, Marino PS, Brett SJ. Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review. Crit Care. 2010;14(5):R169.Price LC Wort SJ Finney SJ Marino PS Brett SJ Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review Crit Care 201014 5 R16910.1186/cc9264321926620858239Search in Google Scholar

90Needham DM, Colantuoni E, Mendez-Tellez PA, et al. Lung protective mechanical ventilation and two year survival in patients with acute lung injury: prospective cohort study. BMJ. 2012;344:e2124.Needham DM Colantuoni E Mendez-Tellez PA et al Lung protective mechanical ventilation and two year survival in patients with acute lung injury: prospective cohort study BMJ 2012344e212410.1136/bmj.e2124332056622491953Search in Google Scholar

91Rush B, Biagioni BJ, Berger L, McDermid R. Mechanical ventilation outcomes in patients with pulmonary hypertension in the United States: A National Retrospective Cohort Analysis. J Intensive Care Med. 2017;32(10):588-92.Rush B Biagioni BJ Berger L McDermid R Mechanical ventilation outcomes in patients with pulmonary hypertension in the United States: A National Retrospective Cohort Analysis J Intensive Care Med 201732 10 588 9210.1177/088506661665392627279084Search in Google Scholar

92Bansal S, Lindenfeld J, Schrier RW. Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist? Circ Heart Fail. 2009;2(4):370-6.Bansal S Lindenfeld J Schrier RW Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist? Circ Heart Fail 20092 4 370 610.1161/CIRCHEARTFAILURE.108.82119919808361Search in Google Scholar

93Felker GM, Mentz RJ. Diuretics and ultrafiltration in acute decompensated heart failure. J Am Coll Cardiol. 2012;59(24):2145-53.Felker GM Mentz RJ Diuretics and ultrafiltration in acute decompensated heart failure J Am Coll Cardiol 201259 24 2145 5310.1016/j.jacc.2011.10.91022676934Search in Google Scholar

94Sitbon O, Vonk Noordegraaf A. Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience. Eur Respir Rev. 2017;26(143):160055.Sitbon O Vonk Noordegraaf A Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience Eur Respir Rev 201726 143 16005510.1183/16000617.0055-201628096285Search in Google Scholar

95Sitbon O, Channick R, Chin KM, et al; GRIPHON Investigators. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522-33.Sitbon O Channick R Chin KM et al GRIPHON Investigators. Selexipag for the treatment of pulmonary arterial hypertension N Engl J Med 2015373 26 2522 3310.1056/NEJMoa150318426699168Search in Google Scholar

96Vachiery JL, Huez S, Gillies H, et al. Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension. Br J Clin Pharmacol 2011;71(2):289-92.Vachiery JL Huez S Gillies H et al Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension Br J Clin Pharmacol 201171 2 289 9210.1111/j.1365-2125.2010.03831.x304055121219411Search in Google Scholar

97Sitbon O, Jais X, Savale L, et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J 2014;43:1691-7.Sitbon O Jais X Savale L et al Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study Eur Respir J 2014431691 710.1183/09031936.0011631324627535Search in Google Scholar

98Appleton C, Gillam L, Koulogiannis K. Cardiac Tamponade. Cardiol Clin. 2017;35(4):525-37.Appleton C Gillam L Koulogiannis K Cardiac Tamponade Cardiol Clin 201735 4 525 3710.1016/j.ccl.2017.07.00629025544Search in Google Scholar

99Schmidt M, Burrell A, Roberts L, et al. Predicting survival after ECMO for refractory cardiogenic shock: the survival after venoarterial-ECMO (SAVE)-score. Eur Heart J. 2015;36(33):2246-56.Schmidt M Burrell A Roberts L et al Predicting survival after ECMO for refractory cardiogenic shock: the survival after venoarterial-ECMO (SAVE)-score Eur Heart J 201536 33 2246 5610.1093/eurheartj/ehv19426033984Search in Google Scholar